Abstract: Immune-related cutaneous adverse reactions caused by immune checkpoint inhibitors in tumor immunotherapy are the earliest and most common adverse reactions, bringing great pain to patients both physically and psychologically. These adverse reactions can even be life-threatening due to delayed or non-standard treatment. The clinical manifestations of immune-related cutaneous adverse reactions are diverse and complex, and there are many uncertainties in their diagnosis and treatment, including whether to discontinue tumor immunotherapy. This consensus makes a systematic analysis, comprehensive evaluation and suggestions on the classification, clinical manifestations, and treatment of cutaneous immune-related adverse events, as well as the consideration of whether to discontinue tumor immunotherapy, hoping to provide help for the standardized diagnosis and treatment of cutaneous immune-related adverse events. In this consensus, it is still emphasized that immune-related adverse events usually involve multiple organs and systems, and attention should be given not only to skin damage but also to potential impacts on the heart, lungs, endocrine system, digestive system, and so on.